LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFbeta derived tetrapeptide and a competitive TGF-beta1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-beta1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier[1][2].
Molecular Weight:
458.60
Purity:
99.84
CAS Number:
[283609-79-0]
Formula:
C21H42N6O5
Target:
TGF-beta Receptor
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
